Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD

Trial Details

NCT ID
NCT05986240
Phase
PHASE1
Sponsor
Montefiore Medical Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Danvatirsen
  • Danvatirsen + Venetoclax
Locations (sample)
  • The Bronx, New York, United States|40.84985,-73.86641
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Subjects must be at least 18 years of age at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF; and be able to meet…
  • Morphologically confirmed diagnosis of AML or MDS in accordance with World Health Organization (WHO) diagnostic criteria
  • Subjects with relapsed/refractory AML who are refractory or relapsed to all conventional therapy and do not have any FDA approved or standard thera…
  • Subjects with MDS/MPN overlap features by NCCN version 3.2026 will also be eligible for the study after they are relapsed or refractory to at least…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →